Gancyclovir-induced megakaryocyte loss in chronic myelogenous leukemia post bone-marrow transplant.
L
L
Gardner
L E
LE
Grosso
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D015774:Ganciclovir / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects*; D013921:Thrombocytopenia / Q000139:chemically induced*
D018906:Antineoplastic Agents, Alkylating; D000998:Antiviral Agents; D007372:Interferons; D015774:Ganciclovir; D006918:Hydroxyurea